Zai Lab (09688) surged 5.06% during intraday trading on Wednesday, reflecting strong market optimism following a significant regulatory milestone.
The surge comes after China's National Medical Products Administration (NMPA) approved the new drug application for xanomeline-trospium chloride capsules (KAI JIE LE), a groundbreaking treatment for adult schizophrenia. This marks the first schizophrenia therapy with a novel mechanism of action approved in over 70 years, positioning Zai Lab for potential revenue growth and market leadership in this therapeutic area.